cyproheptadine (cont.)

Pharmacy Author:
Medical Editor:

Cyproheptadine also can intensify the drying effects on moist tissues (such as the eye or mouth) of other medications with anticholinergic properties (for example, dicyclomine [Bentyl] and bethanechol [Urecholine], probanthine).

PREGNANCY AND BREASTFEEDING SAFETY: Studies in pregnant women have not shown that cyproheptadine harms the fetus during the first, second and third trimesters of pregnancy. However, these studies do not exlude the possibility of harm. Cyproheptadine should be used during pregnancy only if it is clearly needed. It is not known whether cyproheptadine is excreted in human milk.

STORAGE: Cyproheptadine should be stored at room temperature, 15 C - 30 C (59 F - 86 F).

DOSING:

  • The recommended starting dose for adults is 4 mg every 8 hours.
  • The dose range is 4 mg to 20 mg daily.
  • Some patients may require up to 32 mg day. The dose should not exceed 0.5 mg/kg daily.
  • Children 7 to 14 years of age should receive 4 mg 3 times daily. The maximum dose is 16 mg daily.
  • Children 2 to 6 years old are treated with 2 mg three times daily and the maximum dose is 12 mg a day.
  • The total daily dose may also be calculated by weight (0.25 mg/kg/day) or surface area (8 mg/m2).

 

DRUG CLASS AND MECHANISM:

  • Cyproheptadine is an oral antihistamine used for treating allergic reactions.
  • It works by blocking the effects of histamine and is classified as a first generation antihistamine.
  • Histamine is released by cells of the body during several types of allergic reactions and, to a lesser extent, during some viral infections, such as the common cold.
  • When the histamine binds to receptors on other cells, it stimulates changes within the cells that lead to the release of chemicals that cause sneezing, itching, and increased production of mucus. Antihistamines compete with histamine for cell receptors and bind to the receptors without stimulating the cells. In addition, they prevent histamine from binding and stimulating the cells.
  • Cyproheptadine also blocks the action of acetylcholine (anticholinergic effect) and serotonin, two neurotransmitters that nerves and muscles use to communicate with one another, and it causes drowsiness.
  • The FDA approved cyproheptadine in October, 1961.

Reference: FDA Prescribing Information


Medically Reviewed by a Doctor on 1/20/2016


Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index